<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Various Types of VVaccines Categorized by the Antigen Used in the Preparation.</p>
 </caption>
 <alt-text id="alttext0030">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Vaccine</th>
    <th>Structure</th>
    <th>Comments</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="3">
     <bold>Virus vaccines</bold>
    </td>
   </tr>
   <tr>
    <td>Attenuated</td>
    <td>Virus is weakened by passing through animal or human cells, until genome mutates and unable to cause disease</td>
    <td>Inexpensive, rapid production
     <break/>Live vaccine, small chance of disease, replicates
     <break/>Needs cold chain
     <break/>Induces strong long-lasting T cell &amp; B cell immune response
     <break/>Good for attaining herd immunity in the community
     <break/>Vaccine in use: BCG, Smallpox, MMR, Chickenpox, Rotavirus, Yellow fever, Polio (OPV)
    </td>
   </tr>
   <tr>
    <td>Inactivated</td>
    <td>Virus inactivated with formaldehyde or heat</td>
    <td>Noninfectious, cannot cause disease.
     <break/>Can be freeze dried, no cold chain needed
     <break/>Needs adjuvant for immune response
     <break/>Can cause T
     <sub>H</sub>2 cell skewed response (ADE)
     <break/>Vaccines in use: Polio (IPV), HAV, Rabies. Hepatitis A, rabies, Flu.
     <break/>Candidate COVID-19 vaccine: PiCoVacc (Sinovac Biotech)
    </td>
   </tr>
   <tr>
    <td colspan="3">
     <bold>Nucleic acid vaccines</bold>
    </td>
   </tr>
   <tr>
    <td>DNA vaccine</td>
    <td>Gene encoding antigenic components (Spike protein)</td>
    <td>Safe, cannot cause disease.
     <break/>Yet unproven in practice.
     <break/>Can cause T
     <sub>H</sub>2 cell skewed response (ADE) when used alone.
     <break/>Highly immunogenic, generate high titre neutralizing antibodies when given with inactivated vaccine.
     <break/>Electroporation device needed for delivery
     <break/>Candidate COVID-19 vaccine: INO-4800 (Inovio Pharma, CEPI, Korean Institute of Health, International Vaccine Institute)
    </td>
   </tr>
   <tr>
    <td>RNA vaccine</td>
    <td>mRNA vaccine for spike protein, with a lipid coat</td>
    <td>Safe, cannot cause disease,
     <break/>Can cause T
     <sub>H</sub>2 cell skewed response,
     <break/>Yet unproven in practice
     <break/>Candidate COVID-19 vaccine: mRNA-1273 (Moderna/NIAID). BNT162 (a1, b1, b2, c2) (BioNTech/Fosun Pharma/Pfizer)
    </td>
   </tr>
   <tr>
    <td colspan="3">
     <bold>Viral vector vaccines</bold>
    </td>
   </tr>
   <tr>
    <td>Replicating</td>
    <td>An unrelated virus like measles or adenovirus is genetically engineered to encode the gene of interest</td>
    <td>Safe,
     <break/>Induces strong T cell and B cell response,
     <break/>Vaccines in use: Hepatitis B, pertussis, pneumonia caused by 
     <italic>S. pneumoniae</italic>, HPV, Hib (
     <italic>Haemophilus influenza</italic>)
    </td>
   </tr>
   <tr>
    <td>Nonreplicating</td>
    <td>An unrelated virus like measles or adenovirus (with inactive gene) is genetically engineered to encode the gene of interest</td>
    <td>Safe,
     <break/>Need booster shots to induce long-term immunity,
     <break/>No vaccine licensed yet Candidate COVID vaccine: Ad5-nCoV (CanSino Biological Inc./Beijing Institute of Biotechnology). ChAdOx1-nCoV-19 (University of Oxford)
    </td>
   </tr>
   <tr>
    <td colspan="3">
     <bold>Protein-based vaccines</bold>
    </td>
   </tr>
   <tr>
    <td>Subunit</td>
    <td>Antigenic components (spike protein) are generated 
     <italic>inÂ vitro</italic> and harvested for vaccine
    </td>
    <td>Safe,
     <break/>Need multiple dosing and adjuvants
    </td>
   </tr>
   <tr>
    <td>Virus-like particles</td>
    <td>Empty virus shells with no genetic material</td>
    <td>Safe,
     <break/>Strong immune response,
     <break/>Difficult to manufacture
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>ADE, antibody-dependent enhancement.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
